SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

All eyes are on Nvidia's earnings report after the close, with retail sentiment split between expectations of a massive beat and fears of a 'sell the news' drop following its recent losing streak. The broader market is on edge as traders weigh NVDA's results as the key signal for the AI trade's durability amid concerns about customer concentration and rising competition.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending as traders pile in after its H1 earnings showed explosive revenue growth and raised guidance, with bullish chatter about a potential short squeeze colliding with bearish concerns over widening losses and margin pressure.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific (APAC). Its brands include Abercrombie and Hollister. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

ANF is surging after a massive Q2 earnings blowout, record sales, and a raised outlook, sparking intense debate as traders call it a historic short squeeze while skeptics dismiss the gains as a one-time tariff refund. The chatter is split between bullish momentum traders citing the increased buyback and rare shorts, and bears claiming 'irrational exuberance' tied to a $100M tariff windfall.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is surging on its $795M licensing deal with SK Biopharmaceuticals for the epilepsy drug opakalim, which provides non-dilutive cash and de-risks upcoming catalysts. Retail traders are hyped over the extended cash runway and now focus on the pivotal obesity data readout expected in late 2026, seeing the deal as validation of the pipeline.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is swirling with speculation over the U.S. government's stake becoming sellable, while Nancy Pelosi's disclosed purchase and SK Hynix's adoption of its EMIB packaging fuel bullish hopesall ahead of Nvidia's earnings and the CFO's conference appearance.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is under heavy fire as its Q2 report triggered a sharp selloff, with traders hammering the stock for flat revenue and a wider loss while a surge in bookings and backlog has left the community deeply split between 'bookings are the real story' defenders and those calling the valuation a bubble. Adding fuel to the fire, the announcement of CFO John Markovich's retirement is fueling speculation and conspiracy theories, all set against a backdrop of heightened volatility across the quantum computing sector.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RVMD is spiking on FDA approval of daraxonrasib for pancreatic cancer, with the community highlighting data that nearly doubled overall survival and slashed death risk by 60%. The buzz is centered on how this validates the drug's blockbuster potential and fuels speculation about a high-premium buyout from big pharma, while also sparking comparisons to other cancer-focused names like SLS.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

OKLO is trending due to a highly polarized social media debate centered on its nuclear/AI catalyst narrative, including the Groves reactor criticality and major partnership agreements, versus persistent bearish arguments about zero revenue, insider selling, and valuation. This tug-of-war is driving extreme volatility, with bulls pointing to execution milestones and long-term AI power demand, while bears highlight the lack of current financials and short-term price drops.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is getting hammered as Meta's massive youth-addiction settlement shines a spotlight on the legal overhang facing all social media stocks, with a Ninth Circuit ruling denying Section 230 immunity allowing 3,000+ addiction lawsuits to proceed against SNAP, compounded by CTO Robert Murphy's $21.6M insider sale. The community is split between treating this as a stop-loss raid and buying opportunity ahead of the Sept. 16 SPECS launch versus a genuine repricing of litigation exposure.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal is trending on strong Q2 momentum and persistent buyout/M&A speculation, with traders debating whether aggressive spending is a red flag or justified reinvestment in its MASH lead. The community remains split between calling recent volatility an overreaction and worrying about near-term expenses, while broader GLP-1 competition and pipeline expansion keep the story active.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS $MRK $MRNA Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. 
*Phase 3 Trial Results Imminent. 
 
Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. 
$ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. 
GPS MOS in this Same First Remission Setting Achieved PH2 MOS &gt;67.6 Months. 
SOC: 24.7 --- GPs: &gt; 67.6  
Again Note the Key Gps Specific Immune Response. 
Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 
6.7% of the Onureg CR1 Patients Subsequently rec&#39;d transplant.

Jay Glenn

Galarius

Oliver Schermuly

peacewealth7447

Tony M

Nuova Linoleum Gomma

5,500% ROI this quarter

Xuan He

CMSP

$SLS Elahere 16.46 Month MOS for PR/OC  Bought for $10B    
   
GPS /$MRK Key MOS of 18.4 months Same Exact PR/OC Setting.   
   
• Gps is worth $49 Per SLS Share to $MRK JUST for OC.  
  
Merck Dr. Julie Cohen in co-authoring the PH2 Published Data, stated Gps would work even better in a Macroscopic (remission/maintenance Setting - ala the $MRNA Melonoma p3. ) and stated a they should run a P3.....  
  
Gps has proven effective in preventing relapse and extending survival in ALL Previous Trials, including 2 For AML REMISSION Maintenance.

StockTwits Web

SELLAS Life Sciences Group Inc

Merck & Co Inc

Moderna Inc

$SLS $MRK $MRNA Investment Opportunity of a Lifetime for Anyone Investing in SLS ahead of the Imminent Phase 3 Trial Results.  
• 15X ROI any day now. 
Last few days, since the $MRNA Vaccine proved conclusively Cancer Vaccines Work, I&#39;ve posted much DD about Gps, a revolutionary Immunotherapy for AML Remission Maintenance, about to Report Phase 3 Results - that will give Gps the FDA Green light to treat 50,000 AML Remission Patients each year - $28B TAM - and worth 15X the current SLS Mcap. 
 
A Key Note: GPs Efficacy in preventing Relapse, and extending Survival in ALL Prior trials, is correlated w Immune Response -- Gps Specific WT1 Immune Response equals - Extended Survival. 
• the IDMC Unblinded Actual Phase 3 MOS and IR data from the INTERIM Analysis --- back in Jan 2025 -- since then, SLS has been on Fleak -All metrics Up Bigly ...  
• Gps elicited IR in 80% of tested P3 Patients ...  
Go back through my posts and see the correlation -- if you like money.

Abbvie Inc

 Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. 
*Phase 3 Trial Results Imminent. 
 
Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. 


 Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. 
GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. 
SOC: 24.7 --- GPs: > 67.6  
Again Note the Key Gps Specific Immune Response. 
Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 
6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.